Monogram Technologies Receives FDA Request for Additional Information on mBôs TKA System
核心洞察
Monogram Technologies (搜索) received an Additional Information Request (AIR) from the FDA for its mBôs TKA System (搜索), requiring a response within 180 days.
The company plans to conduct clinical trials in India to gather necessary data for the FDA submission, aiming for regulatory clearance in early Q1 2025.
Monogram is pursuing a dual-track approach, addressing the AIR for the semi-active system while advancing its active modality with OUS clinical data.
Monogram Technologies (搜索) Inc. (NASDAQ:MGRM) has announced it received an Additional Information Request (AIR) from the U.S. Food and Drug Administration (FDA) regarding its 510(k) premarket filing for the mBôs TKA System (搜索). The company has 180 days to respond to the AIR, or the application will be considered withdrawn. This development impacts the timeline for FDA clearance of the robotic surgical system designed for total knee arthroplasty.
FDA Response and Company Strategy
The AIR was issued on September 30, 2024, following the initial administrative review of the application submitted on July 19, 2024. Monogram Technologies (搜索) plans to conduct clinical trials to generate the required information, with a focus on gathering data efficiently. CEO Ben Sexson stated that the response provides increased clarity for Monogram's path toward clearance and commercialization.
Monogram is adopting a dual-track approach. While addressing the AIR for its semi-active system, the company will also pursue a submission for its active modality using clinical data obtained outside the United States (OUS). This parallel strategy aims to expedite the overall clearance process.
Clinical Trials and Regulatory Milestones
Upcoming milestones for Monogram include obtaining regulatory clearance to conduct clinical trials in India with strategic partner Shalby Hospitals (搜索), expected in early Q1 2025. These trials are projected to include 92 total knee replacement procedures, with a 3-month clinical follow-up. The company also plans to conduct OUS live-patient surgery trials and submit the resulting clinical trial data to the FDA.
Financial Position and Market Interest
Monogram Technologies (搜索) recently closed an upsized and oversubscribed $13 million public offering. This financial boost will support the company's strategic objectives and the continued development of its orthopedic robotics system. According to Monogram, there is growing surgeon support and market interest in the mBôs TKA System (搜索), particularly the hands-free, fully active version, which the company believes could be a game-changing advancement for the industry.
About the mBôs TKA System
The mBôs precision robotic surgical system is designed to autonomously execute optimized paths for high-precision insertion of Monogram's FDA-cleared mPress (搜索) press-fit implants. The goal is to achieve well-balanced, better-fitting, and bone-sparing knee replacements. Monogram intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other instrumentation necessary for reconstructive joint replacement procedures.